Your browser doesn't support javascript.
loading
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
Pal, Sumanta; Hu-Lieskovan, Siwen; Agarwal, Neeraj.
Affiliation
  • Pal S; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. Electronic address: spal@coh.org.
  • Hu-Lieskovan S; Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Agarwal N; Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Lancet Oncol ; 20(11): 1473-1474, 2019 11.
Article in En | MEDLINE | ID: mdl-31563518
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-10 / Neoplasms Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-10 / Neoplasms Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article